600,000 Shares in Avanos Medical, Inc. $AVNS Acquired by Samson Rock Capital LLP

Samson Rock Capital LLP acquired a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 600,000 shares of the company’s stock, valued at approximately $14,928,000. Avanos Medical accounts for 32.8% of Samson Rock Capital LLP’s portfolio, making the stock its 2nd biggest holding.

Several other hedge funds also recently bought and sold shares of the business. Federated Hermes Inc. increased its stake in Avanos Medical by 2.8% in the fourth quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after purchasing an additional 691 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Avanos Medical by 15.5% during the first quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock valued at $89,000 after purchasing an additional 846 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Avanos Medical by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after purchasing an additional 1,121 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Avanos Medical by 132.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after purchasing an additional 1,423 shares during the last quarter. Finally, Swiss National Bank increased its stake in Avanos Medical by 2.1% in the 4th quarter. Swiss National Bank now owns 91,500 shares of the company’s stock worth $1,028,000 after buying an additional 1,900 shares during the period. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Price Performance

Shares of AVNS stock opened at $24.99 on Monday. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $25.49. The stock’s 50-day moving average is $24.94 and its 200 day moving average is $19.77. The company has a market cap of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.26 earnings per share. Research analysts predict that Avanos Medical, Inc. will post 1.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AVNS has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, July 20th. Finally, Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.